+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Adult Malignant Glioma Therapeutics Market - Growth, Trends, and Forecasts (2020-2025)

  • ID: 4771864
  • Report
  • May 2020
  • Region: Global
  • 116 Pages
  • Mordor Intelligence


  • AbbVie, Inc.
  • Amgen, Inc.
  • Arbor Pharmaceuticals
  • Bio Rad Laboratories
  • F. Hoffmann-La Roche Ltd
  • Merck & Co. Inc.
The development of a promising drug to treat malignant glioma has proved difficult to date, with many promising candidates failing to achieve the desired test results in the past few years.

However, technological advancements in the diagnosis of gliomas and analysis of its progression, through various imaging modalities, have improved survival rates, thereby giving an enhanced edge for rapid evaluation of the efficacy of several pipeline drugs.

North America and Europe are projected to dominate the global adult malignant glioma therapeutics market during the forecast period, primarily due to the significant reimbursement coverage. The market in the Asia Pacific is expected to expand at a significant CAGR between 2020-2025.

According to the World Health Organization, globally, an estimated 245,000 cases of brain and nervous system tumors are reported each year. Glioblastoma multiforme is the most common and the most lethal of these tumors. Gliomas are categorized under rare diseases; however, the incidence rate across the globe has witnessed a steady rise in the last decade. Adoption of novel drug discovery technologies, such as high-throughput screening and TCGA, has reduced the overall drug discovery time and the cost of drug development. This is attributed to a rising number of players participating in new product development and launches in various therapy areas, including glioma.

Key Market Trends

The Glioblastoma Multiforme Segment is Expected to Exhibit the Fastest Growth over the Forecast Period

In terms of type, the global adult malignant glioma therapeutics market has been classified into glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and others. According to the Case Reports in Oncology, 2018, around 200 cases were reported worldwide for glioblastoma multiforme. Consequently, this segment is likely to be the most attractive segment during the forecast period, followed by anaplastic astrocytoma. Intense research and development focus of manufacturers, the presence of significant patient population driving demand for effective therapeutics to improve the overall survival rate, and rapidly increasing the pipeline of innovative novel drugs are attributed to the high growth of the segment.

North America Holds the Largest Market Share

North America is expected to dominate the global market , owing to technological advancement in the adult malignant glioma therapuetics. However, growth of the market in the near future is likely to depend on the combined prospects in technology and opportunity in the developing countries in Asia, such as China, Japan, India, and South Korea. The market in Asia-Pacific is anticipated to register an above average growth rate during the forecast period, owing to a relatively high patient population demanding affordable care and improvements in healthcare infrastructure to aid in the early diagnosis of malignant gliomas.

Competitive Landscape

The leading vendors of the market are expanding their operations in Asian countries (India, China, Japan, and South Korea)m as these economies hold immense potential for glioma products, given the increasing prevalence of neural disorders in the region. The major players operating in the market include Merck & Co. Inc., F. Hoffmann-La Roche Ltd, and Bio-Rad Laboratories, among others.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.
Note: Product cover images may vary from those shown


  • AbbVie, Inc.
  • Amgen, Inc.
  • Arbor Pharmaceuticals
  • Bio Rad Laboratories
  • F. Hoffmann-La Roche Ltd
  • Merck & Co. Inc.

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Incurable Status of the Disease
4.2.2 Global Increase in Aging Population
4.2.3 Increasing Prevalence of Brain Disorders
4.3 Market Restraints
4.3.1 Diminishing Preference for Chemotherapy
4.3.2 Low Approval Rates for Novel Therapeutics for Glioma
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 Type of Disease
5.1.1 Glioblastoma Multiforme
5.1.2 Anaplastic Astrocytoma
5.1.3 Anaplastic Oligodendroglioma
5.1.4 Anaplastic Oligoastrocytoma
5.1.5 Other Types of Disease
5.2 Therapy
5.2.1 Chemotherapy Temozolomide Bevacizumab Carmustine Other Types of Chemotherapy
5.2.2 Targeted Drug Therapy Epidermal Growth Factor Receptor (EGFR) Inhibitors Other Monoclonal Antibodies
5.2.3 Radiation Therapy
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
5.3.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 AbbVie, Inc.
6.1.2 Amgen, Inc.
6.1.3 Arbor Pharmaceuticals
6.1.4 Bio Rad Laboratories
6.1.5 Bristol-Myers Squibb Company
6.1.6 F. Hoffmann-La Roche Ltd
6.1.7 Pfizer, Inc.
6.1.8 Sun Pharmaceuticals Ltd
6.1.9 Merck & Co. Inc.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • AbbVie, Inc.
  • Amgen, Inc.
  • Arbor Pharmaceuticals
  • Bio Rad Laboratories
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Pfizer, Inc.
  • Sun Pharmaceuticals Ltd
  • Merck & Co. Inc.
Note: Product cover images may vary from those shown